 The beaten-up biopharma stock trekked higher after the development-stage company delivered a slew of pipeline updates alongside first quarter 2020 operating results. The small-cap stock has now gained 28 since the beginning of 2020, although shares of AnaptysBio have lost 73 in the last year. The development-stage company has forged collaborations with GlaxoSmithKline in cancer and Bristol-Myers Squibb in inflammatory diseases, which distributes risk and allows the business flexibility to pursue the development of wholly owned assets. 